Rib-X partners with Sanofi to discover and develop antibiotic candidates to treat drug-resistant Gram-positive and Gram-negative pathogens using Rib-X's RX-04 program

Rib-X Pharmaceuticals Inc.

U.S. / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Sanofi

France / Large-Cap Biopharma (>=$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced